Purpose

To find serum tumor markers for predicting the presence of lymphatic metastasis in patients with lung adenocarcinoma, and to explore the diagnostic value of IGFBP7 in predicting if lymphatic metastasis occurs in lung adenocarcinoma.

Methods

The concentration of IGFBP7 in the peripheral blood of 90 serum samples, including 30 patients with lung adenocarcinoma in situ, 30 patients with lung adenocarcinoma metastasis, and 30 normal controls were detected by ELISA. The data were analyzed statistically.

Results

The concentration of IGFBP7 and D-dimer in the metastatic lung adenocarcinoma group was significantly higher than that in the lung adenocarcinoma in situ group (P < 0.05). The expression level of IGFBP7 in serum of patients with lung adenocarcinoma was associated with the clinical stage (P < 0.05) and lymphatic metastasis (P < 0.05). Using the receiver operating characteristic (ROC) curve, the area under the ROC curve of IGFBP7 was 0.901 (95% Confidence Interval was 0.806 to 0.996), and 0.5 was outside the 95% confidence interval (P < 0.05). The difference was statistically significant.

Conclusions

IGFBP7 can predict if the lung adenocarcinoma has lymphatic metastasis, which is helpful to improve the treatment of lung adenocarcinoma, and can be used as a new tumor marker to predict whether the lung adenocarcinoma has lymphatic metastasis or not.

中文翻译：

---

血清IGFBP7预测肺腺癌患者淋巴转移的临床研究

目的

寻找预测肺腺癌患者是否发生淋巴转移的血清肿瘤标志物，探讨IGFBP7在预测肺腺癌是否发生淋巴转移中的诊断价值。

方法

采用ELISA法检测90份血清样本外周血IGFBP7的浓度，其中原位肺腺癌30例，肺腺癌转移30例，正常对照30例。对数据进行统计学分析。

结果

转移性肺腺癌组IGFBP7和D-二聚体浓度显着高于原位肺腺癌组（P < 0.05）。肺腺癌患者血清中IGFBP7的表达水平与临床分期（P < 0.05）和淋巴转移（P < 0.05）相关。使用受试者工作特征（ROC）曲线，IGFBP7 的 ROC 曲线下面积为 0.901（95% 置信区间为 0.806 至 0.996），0.5 在 95% 置信区间外（P < 0.05）。差异具有统计学意义。

结论

IGFBP7可以预测肺腺癌是否有淋巴转移，有助于提高肺腺癌的治疗水平，可作为预测肺腺癌是否有淋巴转移的新的肿瘤标志物。